Please select the option that best describes you:
Topics:
Breast Cancer • Radiation Oncology
Which patient subgroups do you plan to omit regional nodal irradiation for, given the publication of NSABP-51?
Do you feel that 5 years of follow-up is adequate to change management?
If you will defer, how will your approach differ for triple negative vs. ER/PR negative, but HER2+ patients?